Literature DB >> 1287945

Septicaemic melioidosis: a review of 50 cases from Malaysia.

S D Puthucheary1, N Parasakthi, M K Lee.   

Abstract

Fifty cases of septicaemic melioidosis were reviewed. There was a preponderance of disease among males (male:female ratio 3.2:1) and those aged over 30 years. The presenting clinical features were very varied and not pathognomonic, ranging from fever, cough and septicaemia to fulminant septicaemia and shock. Pulmonary involvement was recorded in 58% of the patients. Skin and soft tissue sepsis was seen in 24%, but many had signs and symptoms of multiorgan involvement. Associated underlying illness was identified in 76% of patients, diabetes mellitus being the commonest (38%), while 34% had more than one predisposing factor. The mortality of 65% in our series is a reflection of the less than satisfactory status of the diagnosis and therapy of septicaemic melioidosis. Only 24% of our patients received appropriate empirical antibiotic therapy. A high index of suspicion of melioidosis in endemic areas and the use of appropriate empirical antimicrobial therapy would be a step towards reducing the high mortality rate.

Entities:  

Mesh:

Year:  1992        PMID: 1287945     DOI: 10.1016/0035-9203(92)90191-e

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  39 in total

1.  Recombinant truncated flagellin of Burkholderia pseudomallei as a molecular probe for diagnosis of melioidosis.

Authors:  Yao-Shen Chen; David Shiuan; Ssu-Ching Chen; Soi-Moi Chye; Ya-Lei Chen
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

2.  Brief communication genotyping of Burkholderia pseudomallei revealed high genetic variability among isolates from a single population group.

Authors:  Abdelrahman Mohammad Zueter; Zaidah Abdul Rahman; Chan Yean Yean; Azian Harun
Journal:  Int J Mol Epidemiol Genet       Date:  2015-09-09

3.  Sequence polymorphism and PCR-restriction fragment length polymorphism analysis of the flagellin gene of Burkholderia pseudomallei.

Authors:  Sun Tee Tay; Pui Ching Cheah; Savithiri D Puthucheary
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

Review 4.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

5.  Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei.

Authors:  Sharon J Peacock; Herbert P Schweizer; David A B Dance; Theresa L Smith; Jay E Gee; Vanaporn Wuthiekanun; David DeShazer; Ivo Steinmetz; Patrick Tan; Bart J Currie
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

6.  Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia.

Authors:  Muhammad R A Hassan; Subhada P Pani; Ng P Peng; Kirtanaa Voralu; Natesan Vijayalakshmi; Ranjith Mehanderkar; Norasmidar A Aziz; Edwin Michael
Journal:  BMC Infect Dis       Date:  2010-10-21       Impact factor: 3.090

7.  The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study.

Authors:  Bart J Currie; Linda Ward; Allen C Cheng
Journal:  PLoS Negl Trop Dis       Date:  2010-11-30

8.  Outcomes of patients with melioidosis treated with meropenem.

Authors:  Allen C Cheng; Dale A Fisher; Nicholas M Anstey; Dianne P Stephens; Susan P Jacups; Bart J Currie
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Interaction of insulin with Pseudomonas pseudomallei.

Authors:  D E Woods; A L Jones; P J Hill
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Within-host evolution of Burkholderia pseudomallei in four cases of acute melioidosis.

Authors:  Erin P Price; Heidie M Hornstra; Direk Limmathurotsakul; Tamara L Max; Derek S Sarovich; Amy J Vogler; Julia L Dale; Jennifer L Ginther; Benjamin Leadem; Rebecca E Colman; Jeffrey T Foster; Apichai Tuanyok; David M Wagner; Sharon J Peacock; Talima Pearson; Paul Keim
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.